

**Clinical trial results:****A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma****Summary**

EudraCT number	2010-020347-12
Trial protocol	HU DE BE FR CZ DK IE AT GB GR ES PL IT
Global end of trial date	21 April 2021

**Results information**

Result version number	v1 (current)
This version publication date	06 April 2022
First version publication date	06 April 2022

**Trial information****Trial identification**

Sponsor protocol code	CA204-004
-----------------------	-----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01239797
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	09 August 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 April 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To compare PFS of lenalidomide/low-dose dexamethasone + elotuzumab (LdE) versus lenalidomide/low-dose dexamethasone (Ld) in subjects with relapsed or refractory multiple myeloma (MM) and to compare the ORR of LdE versus Ld.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 June 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 28
Country: Number of subjects enrolled	Austria: 3
Country: Number of subjects enrolled	Belgium: 17
Country: Number of subjects enrolled	Canada: 67
Country: Number of subjects enrolled	Czechia: 24
Country: Number of subjects enrolled	Denmark: 13
Country: Number of subjects enrolled	France: 50
Country: Number of subjects enrolled	Germany: 46
Country: Number of subjects enrolled	Greece: 43
Country: Number of subjects enrolled	Hungary: 7
Country: Number of subjects enrolled	Ireland: 2
Country: Number of subjects enrolled	Israel: 22
Country: Number of subjects enrolled	Italy: 41
Country: Number of subjects enrolled	Japan: 60
Country: Number of subjects enrolled	Poland: 48
Country: Number of subjects enrolled	Romania: 24
Country: Number of subjects enrolled	Spain: 36
Country: Number of subjects enrolled	Switzerland: 1
Country: Number of subjects enrolled	Turkey: 12

Country: Number of subjects enrolled	United Kingdom: 35
Country: Number of subjects enrolled	United States: 67
Worldwide total number of subjects	646
EEA total number of subjects	354

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	276
From 65 to 84 years	363
85 years and over	7

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

646 participants were randomized and 635 were treated. 1 participant was randomized to treatment E-Ld but received treatment Ld.

### Period 1

Period 1 title	Randomized Participants
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Lenalidomide + Dexamethasone + Elotuzumab

Arm description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days until participants met criteria for discontinuation of study drug On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (IV): On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days until participants met criteria for discontinuation of study drug Elotuzumab (BMS-901608; HuLuc63): Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days until participants met criteria for discontinuation of study drug

Arm type	Experimental
Investigational medicinal product name	Elotuzumab
Investigational medicinal product code	
Other name	BMS-901608
Pharmaceutical forms	Powder and solvent for concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days.

Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

25 mg, once daily, on Days 1-21 Repeat every 28 days

Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days. On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days.

Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days

<b>Arm title</b>	Lenalidomide + Dexamethasone
------------------	------------------------------

Arm description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug

Arm type	Experimental
Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days

Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

25 mg, once daily, on Days 1-21 Repeat every 28 days

<b>Number of subjects in period 1</b>	Lenalidomide + Dexamethasone + Elotuzumab	Lenalidomide + Dexamethasone
Started	321	325
Completed	319	316
Not completed	2	9
Participant withdrew consent	1	7
Participant no longer meets study criteria	1	1
Adverse event unrelated to study drug	-	1

**Period 2**

Period 2 title	Treated Participants
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Lenalidomide + Dexamethasone + Elotuzumab

## Arm description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days until participants met criteria for discontinuation of study drug On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (IV): On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days until participants met criteria for discontinuation of study drug Elotuzumab (BMS-901608; HuLuc63): Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days until participants met criteria for discontinuation of study drug

Arm type	Experimental
Investigational medicinal product name	Elotuzumab
Investigational medicinal product code	
Other name	BMS-901608
Pharmaceutical forms	Powder and solvent for concentrate for solution for infusion
Routes of administration	Intravenous use

## Dosage and administration details:

Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days.

Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

## Dosage and administration details:

25 mg, once daily, on Days 1-21 Repeat every 28 days

Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days. On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days.

Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

## Dosage and administration details:

On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days.

<b>Arm title</b>	Lenalidomide + Dexamethasone
------------------	------------------------------

## Arm description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until

participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug

Arm type	Experimental
Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days

Investigational medicinal product name	Lenalidomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

25 mg, once daily, on Days 1-21 Repeat every 28 days

Number of subjects in period 2	Lenalidomide + Dexamethasone + Elotuzumab	Lenalidomide + Dexamethasone
	Started	319
Completed	0	0
Not completed	319	316
Adverse event, serious fatal	1	1
Disease progression	185	185
Participant withdrew consent	6	11
Study drug toxicity	39	45
Participant no longer meets study criteria	2	-
Adverse event unrelated to study drug	31	37
Other reasons	14	14
Participants request to discontinue treatment	28	18
Poor/non-compliance	-	1
Administrative reason by sponsor	13	4

## Baseline characteristics

### Reporting groups

Reporting group title	Lenalidomide + Dexamethasone + Elotuzumab
-----------------------	---

Reporting group description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days until participants met criteria for discontinuation of study drug On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (IV): On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days until participants met criteria for discontinuation of study drug Elotuzumab (BMS-901608; HuLuc63): Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days until participants met criteria for discontinuation of study drug

Reporting group title	Lenalidomide + Dexamethasone
-----------------------	------------------------------

Reporting group description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug

Reporting group values	Lenalidomide + Dexamethasone + Elotuzumab	Lenalidomide + Dexamethasone	Total
Number of subjects	321	325	646
Age Categorical			
Units:			
< 65 years old	134	142	276
>= 65 and < 75 years old	119	122	241
>= 75 years old	68	61	129
Age Continuous			
Units: years			
arithmetic mean	66.2	65.3	-
standard deviation	± 9.34	± 10.26	-
Sex: Female, Male			
Units:			
Female	129	132	261
Male	192	193	385
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	5	1	6
Not Hispanic or Latino	28	33	61
Unknown or Not Reported	288	291	579
Race/Ethnicity, Customized			
Units: Subjects			
White	264	280	544
Black or African American	13	10	23
American Indian or Alaska Native	0	0	0
Asian	33	31	64
Native Hawaiian or Other Pacific Islander	1	0	1
Other	9	4	13

Not Reported	1	0	1
--------------	---	---	---

---

## End points

### End points reporting groups

Reporting group title	Lenalidomide + Dexamethasone + Elotuzumab
-----------------------	---

#### Reporting group description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days until participants met criteria for discontinuation of study drug On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (IV): On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days until participants met criteria for discontinuation of study drug Elotuzumab (BMS-901608; HuLuc63): Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days until participants met criteria for discontinuation of study drug

Reporting group title	Lenalidomide + Dexamethasone
-----------------------	------------------------------

#### Reporting group description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug

Reporting group title	Lenalidomide + Dexamethasone + Elotuzumab
-----------------------	---

#### Reporting group description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days until participants met criteria for discontinuation of study drug On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (IV): On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days until participants met criteria for discontinuation of study drug Elotuzumab (BMS-901608; HuLuc63): Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days until participants met criteria for discontinuation of study drug

Reporting group title	Lenalidomide + Dexamethasone
-----------------------	------------------------------

#### Reporting group description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug

### Primary: Median Progression Free Survival (PFS)

End point title	Median Progression Free Survival (PFS)
-----------------	--

#### End point description:

Primary definition of Progression-free survival (PFS) defined as the time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. The primary analysis of PFS was based on the primary definition using the Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Tumor assessments were made every 4 weeks ( $\pm 1$  week) relative to the first dose of study medication.

End point type	Primary
----------------	---------

#### End point timeframe:

From randomization up to to the date of first documented tumor progression or death (approximately 85 months)

<b>End point values</b>	Lenalidomide + Dexamethasone + Elotuzumab	Lenalidomide + Dexamethasone		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	321	325		
Units: Months				
median (confidence interval 95%)	19.42 (16.62 to 22.31)	14.92 (12.25 to 17.31)		

## Statistical analyses

<b>Statistical analysis title</b>	LdE versus Ld
Statistical analysis description:	
Hazard Ratio of Lenalidomide + Dexamethasone + Elotuzumab to Lenalidomide + Dexamethasone	
Comparison groups	Lenalidomide + Dexamethasone + Elotuzumab v Lenalidomide + Dexamethasone
Number of subjects included in analysis	646
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0005
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	0.87

## Primary: Objective Response Rate (ORR)

<b>End point title</b>	Objective Response Rate (ORR)
End point description:	
Objective response rate (ORR) defined as the number of participants with a best response on-study of partial response (PR) or better (stringent CR [sCR], complete response [CR], very good partial response [VGPR], and partial response [PR]) based on the Independent Review Committee (IRC) assessment of best response using the European Group for Blood and Bone Marrow Transplant (EBMT) assessment criteria. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Assessments were made every 4 weeks.	
End point type	Primary
End point timeframe:	
Randomization up to approximately 52 months	

<b>End point values</b>	Lenalidomide + Dexamethasone + Elotuzumab	Lenalidomide + Dexamethasone		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	321	325		
Units: Participants	272	239		

### Statistical analyses

<b>Statistical analysis title</b>	Ratio of LdE Ld
Comparison groups	Lenalidomide + Dexamethasone + Elotuzumab v Lenalidomide + Dexamethasone
Number of subjects included in analysis	646
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0004
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	2.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.37
upper limit	3

<b>Statistical analysis title</b>	LdE versus Ld
Statistical analysis description: Difference of Lenalidomide + Dexamethasone + Elotuzumab minus Lenalidomide + Dexamethasone computed using the method of DerSimonian and Laird (weighted average over the strata)	
Comparison groups	Lenalidomide + Dexamethasone + Elotuzumab v Lenalidomide + Dexamethasone
Number of subjects included in analysis	646
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in ORR
Point estimate	10.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.4
upper limit	16.4

---

**Secondary: Median Overall Survival (OS)**

---

End point title	Median Overall Survival (OS)
-----------------	------------------------------

---

End point description:

Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has not died, their survival time will be censored at the date of last contact ("last known alive date"). A subject will be censored at the date of randomization if they were randomized but had no follow-up. (Based on Kaplan Meier estimates)

End point type	Secondary
----------------	-----------

---

End point timeframe:

Randomization to the date of death from any cause (up to approximately 9 years)

---

<b>End point values</b>	Lenalidomide + Dexamethason e + Elotuzumab	Lenalidomide + Dexamethason e		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	321	325		
Units: Months				
median (confidence interval 95%)	48.30 (40.34 to 51.94)	39.62 (33.25 to 45.27)		

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Change from baseline of mean score pain severity (BPI-SF)**

---

End point title	Change from baseline of mean score pain severity (BPI-SF)
-----------------	---

---

End point description:

The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.

End point type	Secondary
----------------	-----------

---

End point timeframe:

From baseline up to approximately 38 months

---

<b>End point values</b>	Lenalidomide + Dexamethasone + Elotuzumab	Lenalidomide + Dexamethasone		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	114	152		
Units: Score on a scale				
arithmetic mean (standard deviation)	0.52 ( $\pm$ 2.237)	-0.04 ( $\pm$ 2.408)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline of mean score pain Interference (BPI-SF)

End point title	Change from baseline of mean score pain Interference (BPI-SF)
-----------------	---

End point description:

The change from baseline of the mean score of pain interference at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline up to approximately 38 months

<b>End point values</b>	Lenalidomide + Dexamethasone + Elotuzumab	Lenalidomide + Dexamethasone		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	113	150		
Units: Score on a scale				
arithmetic mean (standard deviation)	0.95 ( $\pm$ 2.466)	0.48 ( $\pm$ 2.868)		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose up to 60 days post last dose of study therapy (Up to approximately 9 years)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Lenalidomide + Dexamethasone
-----------------------	------------------------------

Reporting group description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug

Reporting group title	Lenalidomide + Dexamethasone + Elotuzumab
-----------------------	---

Reporting group description:

Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days until participants met criteria for discontinuation of study drug On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (IV): On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days until participants met criteria for discontinuation of study drug Elotuzumab (BMS-901608; HuLuc63): Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days until participants met criteria for discontinuation of study drug

<b>Serious adverse events</b>	Lenalidomide + Dexamethasone	Lenalidomide + Dexamethasone + Elotuzumab	
Total subjects affected by serious adverse events			
subjects affected / exposed	194 / 317 (61.20%)	238 / 318 (74.84%)	
number of deaths (all causes)	249	226	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Haemangioma of bone			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma in situ			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of unknown primary site			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	3 / 317 (0.95%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	1 / 6	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	0 / 317 (0.00%)	4 / 318 (1.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 3	
Malignant neoplasm progression			
subjects affected / exposed	4 / 317 (1.26%)	5 / 318 (1.57%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 4	0 / 3	
Myelodysplastic syndrome			
subjects affected / exposed	3 / 317 (0.95%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	2 / 3	2 / 2	
deaths causally related to treatment / all	0 / 1	1 / 1	
Prostatic adenoma			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasmacytoma			

subjects affected / exposed	3 / 317 (0.95%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tumour associated fever			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	4 / 317 (1.26%)	10 / 318 (3.14%)	
occurrences causally related to treatment / all	1 / 4	5 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal neoplasm			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Meningioma			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	5 / 317 (1.58%)	6 / 318 (1.89%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 3	0 / 2	
Haemangioma			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Squamous cell carcinoma of skin</b>		
subjects affected / exposed	3 / 317 (0.95%)	12 / 318 (3.77%)
occurrences causally related to treatment / all	0 / 8	4 / 15
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Tonsil cancer</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0
<b>Chronic lymphocytic leukaemia</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Malignant pleural effusion</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Mesothelioma</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Lung cancer metastatic</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Acute erythroid leukaemia</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Acute myeloid leukaemia</b>		

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical fibroxanthoma			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer stage I			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix carcinoma			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal adenocarcinoma			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
External ear neoplasm malignant			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip squamous cell carcinoma			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm malignant			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Non-small cell lung cancer			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Plasma cell myeloma recurrent			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoma			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm rupture			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Orthostatic hypotension			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			

subjects affected / exposed	4 / 317 (1.26%)	10 / 318 (3.14%)
occurrences causally related to treatment / all	3 / 4	10 / 10
deaths causally related to treatment / all	0 / 0	0 / 0
Subclavian vein thrombosis		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Thrombophlebitis		
subjects affected / exposed	2 / 317 (0.63%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Peripheral ischaemia		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Thrombophlebitis superficial		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Embolism		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hypotension		
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Peripheral artery thrombosis		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Venous thrombosis		

subjects affected / exposed	2 / 317 (0.63%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic venous thrombosis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Surgical and medical procedures			
Hip arthroplasty			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	17 / 317 (5.36%)	25 / 318 (7.86%)	
occurrences causally related to treatment / all	5 / 24	9 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	

Asthenia			
subjects affected / exposed	0 / 317 (0.00%)	4 / 318 (1.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chills			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Disease progression			
subjects affected / exposed	10 / 317 (3.15%)	15 / 318 (4.72%)	
occurrences causally related to treatment / all	0 / 10	0 / 15	
deaths causally related to treatment / all	0 / 8	0 / 11	
Malaise			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	4 / 317 (1.26%)	5 / 318 (1.57%)	
occurrences causally related to treatment / all	1 / 4	1 / 5	
deaths causally related to treatment / all	1 / 4	0 / 2	
Hernia			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Immune system disorders</b>			
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
<b>Reproductive system and breast disorders</b>			
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			
Epistaxis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary alveolar haemorrhage			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obliterative bronchiolitis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dyspnoea</b>			
subjects affected / exposed	4 / 317 (1.26%)	4 / 318 (1.26%)	
occurrences causally related to treatment / all	0 / 4	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Haemoptysis</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Organising pneumonia</b>			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pleural effusion</b>			
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory failure</b>			
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Acute respiratory failure</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bronchial disorder</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Chronic obstructive pulmonary disease</b>			

subjects affected / exposed	3 / 317 (0.95%)	5 / 318 (1.57%)	
occurrences causally related to treatment / all	1 / 4	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung disorder			
subjects affected / exposed	1 / 317 (0.32%)	4 / 318 (1.26%)	
occurrences causally related to treatment / all	1 / 1	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bronchial hyperreactivity			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	8 / 317 (2.52%)	11 / 318 (3.46%)	
occurrences causally related to treatment / all	6 / 9	10 / 11	
deaths causally related to treatment / all	1 / 1	1 / 1	
Hypoxia			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	3 / 317 (0.95%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute pulmonary oedema			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			

subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary artery thrombosis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary fibrosis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Depression			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	1 / 317 (0.32%)	4 / 318 (1.26%)	
occurrences causally related to treatment / all	1 / 1	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Product issues</b>			
Device dislocation			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
International normalised ratio increased			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Viral test positive			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia test positive			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Clostridium test positive subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza A virus test positive subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical condition abnormal subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza B virus test positive subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymerase chain reaction positive subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Femoral neck fracture subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture subjects affected / exposed	2 / 317 (0.63%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Humerus fracture			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Compression fracture			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ilium fracture			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stenosis of vesicourethral anastomosis			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	1 / 317 (0.32%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	2 / 317 (0.63%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Soft tissue injury			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Lip injury		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Post procedural haemorrhage		
subjects affected / exposed	2 / 317 (0.63%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Tendon rupture		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Traumatic fracture		
subjects affected / exposed	2 / 317 (0.63%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Road traffic accident		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Accidental overdose		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Chemical burn		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Joint dislocation		

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Limb injury</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Overdose</b>			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Procedural pain</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin laceration</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Spinal fracture</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Toxicity to various agents</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
<b>Acute coronary syndrome</b>			
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Arrhythmia</b>			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cardio-respiratory arrest		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Myocardial infarction		
subjects affected / exposed	3 / 317 (0.95%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Left ventricular failure		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cardiac failure congestive		
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	0 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Acute myocardial infarction		
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Angina pectoris		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Atrial fibrillation		
subjects affected / exposed	9 / 317 (2.84%)	6 / 318 (1.89%)
occurrences causally related to treatment / all	1 / 9	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0
Cardiac failure		

subjects affected / exposed	3 / 317 (0.95%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	2 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Atrioventricular block complete			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	1 / 317 (0.32%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
Myocardial ischaemia			
subjects affected / exposed	2 / 317 (0.63%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute left ventricular failure			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brugada syndrome			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac aneurysm			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	3 / 317 (0.95%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	1 / 4	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hemiparesis			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	2 / 317 (0.63%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Somnolence		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Transient ischaemic attack		
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Cerebral ischaemia		
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Dementia		
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Dizziness		
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Presyncope		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Status epilepticus		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Optic neuritis		

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	2 / 317 (0.63%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Paraparesis			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord disorder			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Spinal cord compression			
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrospinal fluid leakage			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatic encephalopathy</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Ischaemic stroke</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorder</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Sciatica</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Seizure</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>Febrile neutropenia</b>			
subjects affected / exposed	4 / 317 (1.26%)	5 / 318 (1.57%)	
occurrences causally related to treatment / all	2 / 5	4 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Neutropenia</b>			
subjects affected / exposed	4 / 317 (1.26%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	4 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pancytopenia</b>			

subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eosinophilia			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	8 / 317 (2.52%)	11 / 318 (3.46%)	
occurrences causally related to treatment / all	2 / 9	2 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone marrow failure			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	2 / 317 (0.63%)	5 / 318 (1.57%)	
occurrences causally related to treatment / all	0 / 2	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microangiopathic haemolytic anaemia			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Visual impairment			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract nuclear			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	6 / 317 (1.89%)	6 / 318 (1.89%)	
occurrences causally related to treatment / all	4 / 7	4 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Ileus			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus paralytic			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal ulcer			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 317 (0.00%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mouth haemorrhage			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pancreatitis</b>			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Upper gastrointestinal haemorrhage</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Vomiting</b>			
subjects affected / exposed	4 / 317 (1.26%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	3 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nausea</b>			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Inguinal hernia, obstructive</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Lower gastrointestinal haemorrhage</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Subileus</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Abdominal pain upper</b>			

subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diarrhoea			
subjects affected / exposed	12 / 317 (3.79%)	7 / 318 (2.20%)	
occurrences causally related to treatment / all	2 / 13	5 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocutaneous fistula			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Inguinal hernia			

subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritable bowel syndrome			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperbilirubinaemia			

subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cholecystitis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cholecystitis acute</b>			
subjects affected / exposed	0 / 317 (0.00%)	4 / 318 (1.26%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cholecystitis chronic</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin and subcutaneous tissue disorders</b>			
<b>Pustular psoriasis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin haemorrhage</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Rash maculo-papular</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin ulcer</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dermal cyst</b>			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
<b>Haemorrhage urinary tract</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nephrolithiasis</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urinary retention</b>			
subjects affected / exposed	3 / 317 (0.95%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Neurogenic bladder</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal tubular acidosis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Prerenal failure</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Renal failure</b>			
subjects affected / exposed	5 / 317 (1.58%)	4 / 318 (1.26%)	
occurrences causally related to treatment / all	1 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal impairment</b>			

subjects affected / exposed	0 / 317 (0.00%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urinary tract obstruction</b>			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Acute kidney injury</b>			
subjects affected / exposed	8 / 317 (2.52%)	11 / 318 (3.46%)	
occurrences causally related to treatment / all	2 / 8	2 / 12	
deaths causally related to treatment / all	0 / 2	0 / 0	
<b>Haematuria</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Myeloma cast nephropathy</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Endocrine disorders</b>			
<b>Hypothyroidism</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
<b>Arthralgia</b>			
subjects affected / exposed	2 / 317 (0.63%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bone pain</b>			
subjects affected / exposed	0 / 317 (0.00%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Musculoskeletal pain			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle mass			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	3 / 317 (0.95%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			

subjects affected / exposed	5 / 317 (1.58%)	7 / 318 (2.20%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bone lesion</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Osteonecrosis of jaw</b>			
subjects affected / exposed	6 / 317 (1.89%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Exostosis</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Osteonecrosis</b>			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Arthritis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bone cyst</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Osteoarthritis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Spinal stenosis</b>			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Tendonitis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
<b>Diverticulitis</b>			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pyelonephritis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory syncytial virus infection</b>			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin infection</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Streptococcal bacteraemia</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bronchitis</b>			
subjects affected / exposed	8 / 317 (2.52%)	8 / 318 (2.52%)	
occurrences causally related to treatment / all	3 / 8	2 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Clostridium difficile infection</b>			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cytomegalovirus infection		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Endocarditis		
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Enteritis infectious		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Meningitis staphylococcal		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Neutropenic sepsis		
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pyelonephritis acute		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Staphylococcal sepsis		
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Urinary tract infection		

subjects affected / exposed	5 / 317 (1.58%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	1 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urosepsis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Abscess oral</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebral aspergillosis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Osteomyelitis</b>			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pneumonia pneumococcal</b>			
subjects affected / exposed	1 / 317 (0.32%)	3 / 318 (0.94%)	
occurrences causally related to treatment / all	0 / 1	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Staphylococcal bacteraemia</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Tooth abscess</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bacterial sepsis</b>			

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 317 (0.32%)	8 / 318 (2.52%)	
occurrences causally related to treatment / all	0 / 2	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis viral			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia fungal			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Viral diarrhoea			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			

subjects affected / exposed	0 / 317 (0.00%)	3 / 318 (0.94%)
occurrences causally related to treatment / all	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Bacteraemia</b>		
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Device related sepsis</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Febrile infection</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Herpes zoster</b>		
subjects affected / exposed	1 / 317 (0.32%)	4 / 318 (1.26%)
occurrences causally related to treatment / all	1 / 1	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Infection</b>		
subjects affected / exposed	1 / 317 (0.32%)	3 / 318 (0.94%)
occurrences causally related to treatment / all	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Listeriosis</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Lower respiratory tract infection</b>		
subjects affected / exposed	4 / 317 (1.26%)	8 / 318 (2.52%)
occurrences causally related to treatment / all	1 / 5	4 / 9
deaths causally related to treatment / all	0 / 0	1 / 1
<b>Periodontitis</b>		

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Peritonitis		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0
Pharyngitis		
subjects affected / exposed	2 / 317 (0.63%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia		
subjects affected / exposed	40 / 317 (12.62%)	56 / 318 (17.61%)
occurrences causally related to treatment / all	14 / 49	30 / 74
deaths causally related to treatment / all	0 / 3	0 / 3
Septic shock		
subjects affected / exposed	5 / 317 (1.58%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	3 / 6	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1
Sinusitis		
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Influenza		
subjects affected / exposed	4 / 317 (1.26%)	3 / 318 (0.94%)
occurrences causally related to treatment / all	0 / 4	2 / 4
deaths causally related to treatment / all	0 / 0	1 / 1
Pneumocystis jirovecii pneumonia		
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	1 / 1	1 / 2
deaths causally related to treatment / all	1 / 1	0 / 0
Pneumonia bacterial		

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia influenzal		
subjects affected / exposed	2 / 317 (0.63%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory tract infection		
subjects affected / exposed	4 / 317 (1.26%)	11 / 318 (3.46%)
occurrences causally related to treatment / all	2 / 4	6 / 11
deaths causally related to treatment / all	0 / 0	0 / 0
Sepsis		
subjects affected / exposed	8 / 317 (2.52%)	5 / 318 (1.57%)
occurrences causally related to treatment / all	3 / 8	1 / 5
deaths causally related to treatment / all	2 / 5	0 / 2
Upper respiratory tract infection		
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Bronchopulmonary aspergillosis		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Device related infection		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Lung abscess		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumococcal sepsis		

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute sinusitis			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	2 / 317 (0.63%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	4 / 317 (1.26%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	2 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	1 / 317 (0.32%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmic herpes zoster			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection enterococcal			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal abscess			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Appendicitis		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Biliary sepsis		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Brain abscess		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	1 / 1
Bursitis infective		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Catheter site abscess		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Clostridium colitis		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Clostridium difficile colitis		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Cytomegalovirus chorioretinitis		

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Epididymitis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Escherichia urinary tract infection</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastroenteritis clostridial</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastroenteritis norovirus</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatitis B</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Genital abscess</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Herpes zoster reactivation</b>			
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infective exacerbation of chronic obstructive airways disease</b>			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Intervertebral discitis</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Large intestine infection</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Metapneumovirus infection</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Localised infection</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Otitis media chronic</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Parvovirus B19 infection</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Post procedural infection</b>		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Pseudomonal sepsis</b>		

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pseudomonas infection</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pulmonary sepsis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Retinitis</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Rotavirus infection</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Systemic infection</b>			
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Varicella zoster virus infection</b>			
subjects affected / exposed	0 / 317 (0.00%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metabolism and nutrition disorders</b>			
<b>Dehydration</b>			
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hyponatraemia</b>			

subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Failure to thrive		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Hypoglycaemia		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hypocalcaemia		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hypokalaemia		
subjects affected / exposed	2 / 317 (0.63%)	3 / 318 (0.94%)
occurrences causally related to treatment / all	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Hypercalcaemia		
subjects affected / exposed	2 / 317 (0.63%)	3 / 318 (0.94%)
occurrences causally related to treatment / all	1 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Tumour lysis syndrome		
subjects affected / exposed	1 / 317 (0.32%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Decreased appetite		
subjects affected / exposed	1 / 317 (0.32%)	2 / 318 (0.63%)
occurrences causally related to treatment / all	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Diabetes mellitus		

subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Hyperglycaemia</b>		
subjects affected / exposed	1 / 317 (0.32%)	3 / 318 (0.94%)
occurrences causally related to treatment / all	1 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Fluid retention</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Ketoacidosis</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Type 2 diabetes mellitus</b>		
subjects affected / exposed	0 / 317 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Lenalidomide + Dexamethasone	Lenalidomide + Dexamethasone + Elotuzumab
<b>Total subjects affected by non-serious adverse events</b>		
subjects affected / exposed	309 / 317 (97.48%)	314 / 318 (98.74%)
<b>Vascular disorders</b>		
<b>Hypertension</b>		
subjects affected / exposed	23 / 317 (7.26%)	40 / 318 (12.58%)
occurrences (all)	33	62
<b>Deep vein thrombosis</b>		
subjects affected / exposed	10 / 317 (3.15%)	19 / 318 (5.97%)
occurrences (all)	10	21
<b>Hypotension</b>		

subjects affected / exposed occurrences (all)	12 / 317 (3.79%) 13	33 / 318 (10.38%) 44
Flushing subjects affected / exposed occurrences (all)	6 / 317 (1.89%) 6	16 / 318 (5.03%) 21
Haematoma subjects affected / exposed occurrences (all)	8 / 317 (2.52%) 9	17 / 318 (5.35%) 18
General disorders and administration site conditions		
Oedema peripheral subjects affected / exposed occurrences (all)	78 / 317 (24.61%) 100	97 / 318 (30.50%) 172
Chest pain subjects affected / exposed occurrences (all)	14 / 317 (4.42%) 14	28 / 318 (8.81%) 32
Influenza like illness subjects affected / exposed occurrences (all)	16 / 317 (5.05%) 24	27 / 318 (8.49%) 38
Pyrexia subjects affected / exposed occurrences (all)	74 / 317 (23.34%) 106	121 / 318 (38.05%) 235
Asthenia subjects affected / exposed occurrences (all)	54 / 317 (17.03%) 85	80 / 318 (25.16%) 128
Chills subjects affected / exposed occurrences (all)	12 / 317 (3.79%) 12	31 / 318 (9.75%) 38
Fatigue subjects affected / exposed occurrences (all)	131 / 317 (41.32%) 159	154 / 318 (48.43%) 229
Malaise subjects affected / exposed occurrences (all)	12 / 317 (3.79%) 12	19 / 318 (5.97%) 24
Pain		

subjects affected / exposed occurrences (all)	7 / 317 (2.21%) 8	17 / 318 (5.35%) 19	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea exertional subjects affected / exposed occurrences (all)	15 / 317 (4.73%) 15	20 / 318 (6.29%) 21	
Epistaxis subjects affected / exposed occurrences (all)	19 / 317 (5.99%) 22	22 / 318 (6.92%) 24	
Oropharyngeal pain subjects affected / exposed occurrences (all)	15 / 317 (4.73%) 20	32 / 318 (10.06%) 48	
Cough subjects affected / exposed occurrences (all)	62 / 317 (19.56%) 95	109 / 318 (34.28%) 188	
Dyspnoea subjects affected / exposed occurrences (all)	60 / 317 (18.93%) 74	72 / 318 (22.64%) 108	
Productive cough subjects affected / exposed occurrences (all)	5 / 317 (1.58%) 5	25 / 318 (7.86%) 32	
Dysphonia subjects affected / exposed occurrences (all)	32 / 317 (10.09%) 33	25 / 318 (7.86%) 28	
Psychiatric disorders			
Mood altered subjects affected / exposed occurrences (all)	8 / 317 (2.52%) 8	23 / 318 (7.23%) 25	
Depression subjects affected / exposed occurrences (all)	14 / 317 (4.42%) 15	18 / 318 (5.66%) 19	
Insomnia subjects affected / exposed occurrences (all)	83 / 317 (26.18%) 112	79 / 318 (24.84%) 90	
Anxiety			

subjects affected / exposed occurrences (all)	24 / 317 (7.57%) 26	26 / 318 (8.18%) 27	
Confusional state subjects affected / exposed occurrences (all)	10 / 317 (3.15%) 10	18 / 318 (5.66%) 28	
Investigations			
Blood creatinine increased subjects affected / exposed occurrences (all)	27 / 317 (8.52%) 38	36 / 318 (11.32%) 76	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	31 / 317 (9.78%) 49	21 / 318 (6.60%) 26	
Weight decreased subjects affected / exposed occurrences (all)	20 / 317 (6.31%) 21	52 / 318 (16.35%) 54	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	33 / 317 (10.41%) 70	25 / 318 (7.86%) 37	
Platelet count decreased subjects affected / exposed occurrences (all)	5 / 317 (1.58%) 8	16 / 318 (5.03%) 28	
C-reactive protein increased subjects affected / exposed occurrences (all)	16 / 317 (5.05%) 25	13 / 318 (4.09%) 25	
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	28 / 317 (8.83%) 33	44 / 318 (13.84%) 54	
Fall subjects affected / exposed occurrences (all)	14 / 317 (4.42%) 21	21 / 318 (6.60%) 27	
Nervous system disorders			
Hypoaesthesia subjects affected / exposed occurrences (all)	12 / 317 (3.79%) 12	28 / 318 (8.81%) 31	
Headache			

subjects affected / exposed	29 / 317 (9.15%)	54 / 318 (16.98%)
occurrences (all)	53	104
<b>Paraesthesia</b>		
subjects affected / exposed	29 / 317 (9.15%)	35 / 318 (11.01%)
occurrences (all)	35	40
<b>Peripheral sensory neuropathy</b>		
subjects affected / exposed	39 / 317 (12.30%)	33 / 318 (10.38%)
occurrences (all)	47	37
<b>Dizziness</b>		
subjects affected / exposed	38 / 317 (11.99%)	48 / 318 (15.09%)
occurrences (all)	45	76
<b>Tremor</b>		
subjects affected / exposed	29 / 317 (9.15%)	30 / 318 (9.43%)
occurrences (all)	35	34
<b>Neuropathy peripheral</b>		
subjects affected / exposed	31 / 317 (9.78%)	51 / 318 (16.04%)
occurrences (all)	34	56
<b>Taste disorder</b>		
subjects affected / exposed	14 / 317 (4.42%)	18 / 318 (5.66%)
occurrences (all)	14	19
<b>Blood and lymphatic system disorders</b>		
<b>Leukopenia</b>		
subjects affected / exposed	26 / 317 (8.20%)	26 / 318 (8.18%)
occurrences (all)	73	72
<b>Neutropenia</b>		
subjects affected / exposed	137 / 317 (43.22%)	114 / 318 (35.85%)
occurrences (all)	476	365
<b>Anaemia</b>		
subjects affected / exposed	118 / 317 (37.22%)	135 / 318 (42.45%)
occurrences (all)	229	289
<b>Thrombocytopenia</b>		
subjects affected / exposed	72 / 317 (22.71%)	91 / 318 (28.62%)
occurrences (all)	173	215
<b>Lymphopenia</b>		
subjects affected / exposed	23 / 317 (7.26%)	41 / 318 (12.89%)
occurrences (all)	60	92

Eye disorders			
Vision blurred			
subjects affected / exposed	18 / 317 (5.68%)	31 / 318 (9.75%)	
occurrences (all)	21	33	
Cataract			
subjects affected / exposed	36 / 317 (11.36%)	58 / 318 (18.24%)	
occurrences (all)	37	65	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	31 / 317 (9.78%)	44 / 318 (13.84%)	
occurrences (all)	39	49	
Constipation			
subjects affected / exposed	89 / 317 (28.08%)	115 / 318 (36.16%)	
occurrences (all)	117	184	
Dyspepsia			
subjects affected / exposed	19 / 317 (5.99%)	36 / 318 (11.32%)	
occurrences (all)	26	50	
Vomiting			
subjects affected / exposed	32 / 317 (10.09%)	58 / 318 (18.24%)	
occurrences (all)	42	88	
Stomatitis			
subjects affected / exposed	14 / 317 (4.42%)	30 / 318 (9.43%)	
occurrences (all)	16	36	
Nausea			
subjects affected / exposed	73 / 317 (23.03%)	82 / 318 (25.79%)	
occurrences (all)	99	129	
Abdominal pain upper			
subjects affected / exposed	20 / 317 (6.31%)	30 / 318 (9.43%)	
occurrences (all)	25	33	
Diarrhoea			
subjects affected / exposed	122 / 317 (38.49%)	159 / 318 (50.00%)	
occurrences (all)	247	451	
Dry mouth			
subjects affected / exposed	10 / 317 (3.15%)	16 / 318 (5.03%)	
occurrences (all)	10	16	
Toothache			

subjects affected / exposed occurrences (all)	11 / 317 (3.47%) 12	18 / 318 (5.66%) 23	
<b>Skin and subcutaneous tissue disorders</b>			
Pruritus			
subjects affected / exposed	29 / 317 (9.15%)	36 / 318 (11.32%)	
occurrences (all)	31	47	
Rash			
subjects affected / exposed	58 / 317 (18.30%)	63 / 318 (19.81%)	
occurrences (all)	93	105	
Hyperhidrosis			
subjects affected / exposed	25 / 317 (7.89%)	38 / 318 (11.95%)	
occurrences (all)	33	46	
Erythema			
subjects affected / exposed	16 / 317 (5.05%)	26 / 318 (8.18%)	
occurrences (all)	22	28	
Night sweats			
subjects affected / exposed	10 / 317 (3.15%)	24 / 318 (7.55%)	
occurrences (all)	13	34	
<b>Renal and urinary disorders</b>			
Dysuria			
subjects affected / exposed	9 / 317 (2.84%)	16 / 318 (5.03%)	
occurrences (all)	9	19	
<b>Musculoskeletal and connective tissue disorders</b>			
Arthralgia			
subjects affected / exposed	63 / 317 (19.87%)	98 / 318 (30.82%)	
occurrences (all)	78	135	
Bone pain			
subjects affected / exposed	43 / 317 (13.56%)	33 / 318 (10.38%)	
occurrences (all)	54	42	
Myalgia			
subjects affected / exposed	22 / 317 (6.94%)	26 / 318 (8.18%)	
occurrences (all)	25	29	
Muscle spasms			
subjects affected / exposed	85 / 317 (26.81%)	99 / 318 (31.13%)	
occurrences (all)	112	145	
Neck pain			

subjects affected / exposed	13 / 317 (4.10%)	23 / 318 (7.23%)
occurrences (all)	14	27
Muscular weakness		
subjects affected / exposed	28 / 317 (8.83%)	42 / 318 (13.21%)
occurrences (all)	31	45
Musculoskeletal chest pain		
subjects affected / exposed	30 / 317 (9.46%)	39 / 318 (12.26%)
occurrences (all)	31	47
Pain in extremity		
subjects affected / exposed	35 / 317 (11.04%)	64 / 318 (20.13%)
occurrences (all)	43	88
Back pain		
subjects affected / exposed	97 / 317 (30.60%)	105 / 318 (33.02%)
occurrences (all)	122	144
<b>Infections and infestations</b>		
Bronchitis		
subjects affected / exposed	52 / 317 (16.40%)	66 / 318 (20.75%)
occurrences (all)	81	124
Nasopharyngitis		
subjects affected / exposed	60 / 317 (18.93%)	83 / 318 (26.10%)
occurrences (all)	128	236
Urinary tract infection		
subjects affected / exposed	31 / 317 (9.78%)	36 / 318 (11.32%)
occurrences (all)	64	65
Rhinitis		
subjects affected / exposed	13 / 317 (4.10%)	30 / 318 (9.43%)
occurrences (all)	17	34
Herpes zoster		
subjects affected / exposed	5 / 317 (1.58%)	18 / 318 (5.66%)
occurrences (all)	5	19
Lower respiratory tract infection		
subjects affected / exposed	16 / 317 (5.05%)	32 / 318 (10.06%)
occurrences (all)	21	70
Pharyngitis		
subjects affected / exposed	16 / 317 (5.05%)	17 / 318 (5.35%)
occurrences (all)	29	18

Pneumonia			
subjects affected / exposed	23 / 317 (7.26%)	30 / 318 (9.43%)	
occurrences (all)	29	36	
Sinusitis			
subjects affected / exposed	15 / 317 (4.73%)	23 / 318 (7.23%)	
occurrences (all)	37	52	
Influenza			
subjects affected / exposed	17 / 317 (5.36%)	25 / 318 (7.86%)	
occurrences (all)	26	32	
Respiratory tract infection			
subjects affected / exposed	32 / 317 (10.09%)	36 / 318 (11.32%)	
occurrences (all)	63	67	
Upper respiratory tract infection			
subjects affected / exposed	62 / 317 (19.56%)	86 / 318 (27.04%)	
occurrences (all)	146	209	
Oral herpes			
subjects affected / exposed	13 / 317 (4.10%)	20 / 318 (6.29%)	
occurrences (all)	16	30	
Gastroenteritis			
subjects affected / exposed	9 / 317 (2.84%)	18 / 318 (5.66%)	
occurrences (all)	13	20	
Viral infection			
subjects affected / exposed	10 / 317 (3.15%)	18 / 318 (5.66%)	
occurrences (all)	16	36	
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	10 / 317 (3.15%)	18 / 318 (5.66%)	
occurrences (all)	17	41	
Hypomagnesaemia			
subjects affected / exposed	5 / 317 (1.58%)	22 / 318 (6.92%)	
occurrences (all)	5	46	
Hypocalcaemia			
subjects affected / exposed	28 / 317 (8.83%)	48 / 318 (15.09%)	
occurrences (all)	71	135	
Hypokalaemia			

subjects affected / exposed	47 / 317 (14.83%)	67 / 318 (21.07%)
occurrences (all)	103	124
Decreased appetite		
subjects affected / exposed	42 / 317 (13.25%)	71 / 318 (22.33%)
occurrences (all)	48	93
Hyperglycaemia		
subjects affected / exposed	45 / 317 (14.20%)	61 / 318 (19.18%)
occurrences (all)	87	129
Hypoalbuminaemia		
subjects affected / exposed	11 / 317 (3.47%)	17 / 318 (5.35%)
occurrences (all)	21	22
Hypophosphataemia		
subjects affected / exposed	10 / 317 (3.15%)	19 / 318 (5.97%)
occurrences (all)	33	45

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 March 2012	Clarification of subject eligibility or study procedures
14 April 2014	Addition of formal interim analyses.
14 April 2014	The addition of a secondary and exploratory objectives and the removal Brief Pain Inventory assessment as exploratory endpoint.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported